With its H123 interim results, ReNeuron highlighted progress across its proprietary exosome platform, CustomEx. The company reported H123 revenues of £438k (H122: £58k), primarily related to income associated with a £320k payment from Fosun Pharma as part of a technology transfer and supply agreement. ReNeuron pared back its operating losses (£4.3m in H123, down from £6.1m in H122), largely with reduced clinical trial-related costs following the company’s strategic refocus on exosomes. ReNeuron ....
06 Dec 2022
ReNeuron Group - Pushing on with CustomEx in H123
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
ReNeuron Group - Pushing on with CustomEx in H123
ReNeuron Group plc (RENE:LON) | 0 0 0.0% | Mkt Cap: 1.74m
- Published:
06 Dec 2022 -
Author:
Soo Romanoff -
Pages:
4
With its H123 interim results, ReNeuron highlighted progress across its proprietary exosome platform, CustomEx. The company reported H123 revenues of £438k (H122: £58k), primarily related to income associated with a £320k payment from Fosun Pharma as part of a technology transfer and supply agreement. ReNeuron pared back its operating losses (£4.3m in H123, down from £6.1m in H122), largely with reduced clinical trial-related costs following the company’s strategic refocus on exosomes. ReNeuron ....